Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ARS Pharmaceuticals (SPRY) Depreciation & Amortization (CF) (2021 - 2025)

ARS Pharmaceuticals' Depreciation & Amortization (CF) history spans 5 years, with the latest figure at $417000.0 for Q4 2025.

  • For Q4 2025, Depreciation & Amortization (CF) rose 1337.93% year-over-year to $417000.0; the TTM value through Dec 2025 reached $1.4 million, up 1630.38%, while the annual FY2025 figure was $1.4 million, 1630.38% up from the prior year.
  • Depreciation & Amortization (CF) for Q4 2025 was $417000.0 at ARS Pharmaceuticals, up from $391000.0 in the prior quarter.
  • Across five years, Depreciation & Amortization (CF) topped out at $417000.0 in Q4 2025 and bottomed at -$37000.0 in Q2 2022.
  • The 5-year median for Depreciation & Amortization (CF) is $29000.0 (2024), against an average of $131526.3.
  • The largest annual shift saw Depreciation & Amortization (CF) crashed 117.7% in 2022 before it skyrocketed 2445.45% in 2025.
  • A 5-year view of Depreciation & Amortization (CF) shows it stood at $204000.0 in 2021, then crashed by 93.14% to $14000.0 in 2022, then soared by 50.0% to $21000.0 in 2023, then surged by 38.1% to $29000.0 in 2024, then surged by 1337.93% to $417000.0 in 2025.
  • Per Business Quant, the three most recent readings for SPRY's Depreciation & Amortization (CF) are $417000.0 (Q4 2025), $391000.0 (Q3 2025), and $279000.0 (Q2 2025).